{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:18:25Z","timestamp":1793884705679,"version":"4.7.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172865"],"award-info":[{"award-number":["82172865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-72760-x","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:02:26Z","timestamp":1726207346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC"],"prefix":"10.1038","volume":"14","author":[{"given":"Qian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Butuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"72760_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin.74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"72760_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"72760_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus Docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N. Engl. J. Med.373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"72760_CR4","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus Docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 387, 1540\u20131550 (2016).","journal-title":"Lancet"},{"key":"72760_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 389, 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"72760_CR6","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien, M. et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol.23, 1274\u20131286 (2022).","journal-title":"Lancet Oncol."},{"key":"72760_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 398, 1344\u20131357 (2021).","journal-title":"Lancet"},{"key":"72760_CR8","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde, P. M. et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med.386, 1973\u20131985 (2022).","journal-title":"N. Engl. J. Med."},{"key":"72760_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee, H. et al. Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer. N. Engl. J. Med.389, 491\u2013503 (2023).","journal-title":"N. Engl. J. Med."},{"key":"72760_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. J. Clin. Oncol.40, 1301 (2022).","journal-title":"J. Clin. Oncol."},{"key":"72760_CR11","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","volume":"18","author":"JR Brahmer","year":"2017","unstructured":"Brahmer, J. R. et al. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet Oncol.18, 1600\u20131609 (2017).","journal-title":"Lancet Oncol."},{"key":"72760_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino, M. C. et al. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol.21, 387\u2013397 (2020).","journal-title":"Lancet Oncol."},{"key":"72760_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares, L. et al. A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. J. Thorac. Oncol.15, 1657\u20131669 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"72760_CR14","doi-asserted-by":"crossref","unstructured":"Reck, M. et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. (2019).","DOI":"10.1200\/JCO.18.00149"},{"key":"72760_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol.16, 223\u2013249 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"72760_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita, L. et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non\u2013small cell lung cancer. JAMA Oncol.4, 351\u2013357 (2018).","journal-title":"JAMA Oncol."},{"key":"72760_CR17","doi-asserted-by":"publisher","first-page":"6291","DOI":"10.1002\/cam4.4171","volume":"10","author":"Q Zhao","year":"2021","unstructured":"Zhao, Q. et al. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer. Cancer Med.10, 6291\u20136303 (2021).","journal-title":"Cancer Med."},{"key":"72760_CR18","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.7150\/ijbs.71046","volume":"18","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. The progress of multimodal imaging combination and subregion based radiomics research of cancers. Int. J. Biol. Sci.18, 3458 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"72760_CR19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/cancers14020350","volume":"14","author":"E Barabino","year":"2022","unstructured":"Barabino, E. et al. Exploring response to immunotherapy in non-small cell lung cancer using delta-radiomics. Cancers. 14, 350 (2022).","journal-title":"Cancers"},{"key":"72760_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41467-019-08538-x","volume":"10","author":"X Yu","year":"2019","unstructured":"Yu, X. et al. Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis. Nat. Commun.10, 574 (2019).","journal-title":"Nat. Commun."},{"key":"72760_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer cell.29, 285\u2013296 (2016).","journal-title":"Cancer cell."},{"key":"72760_CR22","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1158\/1078-0432.CCR-08-0133","volume":"14","author":"KI Al-Shibli","year":"2008","unstructured":"Al-Shibli, K. I. et al. Prognostic effect of epithelial and stromal lymphocyte infiltration in non\u2013small cell lung cancer. Clin. Cancer Res.14, 5220\u20135227 (2008).","journal-title":"Clin. Cancer Res."},{"key":"72760_CR23","doi-asserted-by":"publisher","first-page":"dju435","DOI":"10.1093\/jnci\/dju435","volume":"107","author":"KA Schalper","year":"2015","unstructured":"Schalper, K. A. et al. Objective measurement and clinical significance of TILs in non\u2013small cell lung cancer. J. Natl Cancer Inst.107, dju435 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"72760_CR24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1093\/annonc\/mdw319","volume":"27","author":"T Kinoshita","year":"2016","unstructured":"Kinoshita, T. et al. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann. Oncol.27, 2117\u20132123 (2016).","journal-title":"Ann. Oncol."},{"key":"72760_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1164\/rccm.201309-1611OC","volume":"189","author":"C Germain","year":"2014","unstructured":"Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit Care Med.189, 832\u2013844 (2014).","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"72760_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Reviews Clin. Oncol.18, 85\u2013100 (2021).","journal-title":"Nat. Reviews Clin. Oncol."},{"key":"72760_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cac2.12394","volume":"43","author":"F Ghaedrahmati","year":"2023","unstructured":"Ghaedrahmati, F., Esmaeil, N. & Abbaspour, M. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Commun.43, 177\u2013213 (2023).","journal-title":"Cancer Commun."},{"key":"72760_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang, X., Wang, J., Lu, D. & Xu, X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal. Transduct. Target. Therapy. 6, 75 (2021).","journal-title":"Signal. Transduct. Target. Therapy"},{"key":"72760_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40364-023-00460-1","volume":"11","author":"E Zhang","year":"2023","unstructured":"Zhang, E. et al. Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomark. Res.11, 28 (2023).","journal-title":"Biomark. Res."},{"key":"72760_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.prp.2014.12.013","volume":"211","author":"S Amoueian","year":"2015","unstructured":"Amoueian, S., Attaranzadeh, A. & Montazer, M. Intratumoral CD68-, CD117-, CD56-, and CD1a-positive immune cells and the survival of Iranian patients with non-metastatic intestinal-type gastric carcinoma. Pathology-Research Pract.211, 326\u2013331 (2015).","journal-title":"Pathology-Research Pract."},{"key":"72760_CR31","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.21037\/jtd.2019.12.24","volume":"11","author":"Y Saito","year":"2019","unstructured":"Saito, Y. et al. Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer. J. Thorac. Disease. 11, 4982 (2019).","journal-title":"J. Thorac. Disease"},{"key":"72760_CR32","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0169-5002(19)30205-3","volume":"127","author":"R Moor","year":"2019","unstructured":"Moor, R., O\u2019Byrne, K. & Roberts, K. Modified lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients. Lung Cancer. 127, S67\u2013S68 (2019).","journal-title":"Lung Cancer"},{"key":"72760_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.71, 209\u2013249 (2021).","journal-title":"Cancer J. Clin."},{"key":"72760_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai, R., Lv, Z., Xu, D. & Cui, J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark. Res.8, 1\u201317 (2020).","journal-title":"Biomark. Res."},{"key":"72760_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","volume":"5","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian, D., Gong, Y., Keegan, P., Pazdur, R. & Blumenthal, G. M. Prognostic value of the lung immune prognostic index for patients treated for metastatic non\u2013small cell lung cancer. JAMA Oncol.5, 1481\u20131485 (2019).","journal-title":"JAMA Oncol."},{"key":"72760_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2018.11.002","volume":"106","author":"A Prelaj","year":"2019","unstructured":"Prelaj, A. et al. Predictive biomarkers of response for immune checkpoint inhibitors in non\u2013small-cell lung cancer. Eur. J. Cancer. 106, 144\u2013159 (2019).","journal-title":"Eur. J. Cancer"},{"key":"72760_CR37","doi-asserted-by":"crossref","unstructured":"Hwang, M. et al. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J. Immunother. Cancer10 (2022).","DOI":"10.1136\/jitc-2022-004688"},{"key":"72760_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12885-023-10502-4","volume":"23","author":"X Du","year":"2023","unstructured":"Du, X. et al. Peripheral blood lymphocytes differentiation patterns in responses\/outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study. BMC cancer. 23, 83 (2023).","journal-title":"BMC cancer"},{"key":"72760_CR39","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrc3611","volume":"13","author":"E Elinav","year":"2013","unstructured":"Elinav, E. et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer. 13, 759\u2013771 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"72760_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s12325-020-01229-w","volume":"37","author":"A Russo","year":"2020","unstructured":"Russo, A. et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study. Adv. Therapy. 37, 1145\u20131155 (2020).","journal-title":"Adv. Therapy"},{"key":"72760_CR41","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metabol.24, 657\u2013671 (2016).","journal-title":"Cell Metabol."},{"key":"72760_CR42","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/annonc\/mdx034","volume":"28","author":"EJ Limkin","year":"2017","unstructured":"Limkin, E. J. et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann. Oncol.28, 1191\u20131206 (2017).","journal-title":"Ann. Oncol."},{"key":"72760_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-019-0223-7","volume":"19","author":"SR Digumarthy","year":"2019","unstructured":"Digumarthy, S. R. et al. Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? Cancer Imaging. 19, 1\u20138 (2019).","journal-title":"Cancer Imaging"},{"key":"72760_CR44","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1158\/1078-0432.CCR-17-2507","volume":"24","author":"J Song","year":"2018","unstructured":"Song, J. et al. A New Approach to predict progression-free survival in Stage IV EGFR-mutant NSCLC patients with EGFR-TKI TherapyPrediction of EGFR-TKI Treatment Outcome in Stage IV NSCLC. Clin. Cancer Res.24, 3583\u20133592 (2018).","journal-title":"Clin. Cancer Res."},{"key":"72760_CR45","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/ijms22105123","volume":"22","author":"E Munari","year":"2021","unstructured":"Munari, E. et al. PD-1\/PD-L1 in cancer: pathophysiological, diagnostic and therapeutic aspects. Int. J. Mol. Sci.22, 5123 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"72760_CR46","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N engl. J. med.375, 1823\u20131833 (2016).","journal-title":"N engl. J. med."},{"key":"72760_CR47","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"E Aguilar","year":"2019","unstructured":"Aguilar, E. et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann. Oncol.30, 1653\u20131659 (2019).","journal-title":"Ann. Oncol."},{"key":"72760_CR48","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","volume":"8","author":"B Ricciuti","year":"2022","unstructured":"Ricciuti, B. et al. Association of high tumor mutation burden in non\u2013small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol.8, 1160\u20131168 (2022).","journal-title":"JAMA Oncol."},{"key":"72760_CR49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger, D. S. et al. Non\u2013small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw.20, 497\u2013530 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"72760_CR50","doi-asserted-by":"publisher","first-page":"9414","DOI":"10.3390\/ijms22179414","volume":"22","author":"HJ An","year":"2021","unstructured":"An, H. J., Chon, H. J. & Kim, C. Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int. J. Mol. Sci.22, 9414 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"72760_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2018","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. immunity39, 1\u201310 (2013).","journal-title":"immunity"},{"key":"72760_CR52","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00262-018-2235-8","volume":"67","author":"C Yang","year":"2018","unstructured":"Yang, C. et al. Anergic natural killer cells educated by tumor cells are associated with a poor prognosis in patients with advanced pancreatic ductal adenocarcinoma. Cancer Immunol. Immunother.67, 1815\u20131823 (2018).","journal-title":"Cancer Immunol. Immunother."},{"key":"72760_CR53","doi-asserted-by":"publisher","first-page":"e1527498","DOI":"10.1080\/2162402X.2018.1527498","volume":"8","author":"E Picard","year":"2019","unstructured":"Picard, E. et al. Circulating NKp46\u2009+\u2009natural killer cells have a potential regulatory property and predict distinct survival in Non-small Cell Lung Cancer. Oncoimmunology. 8, e1527498 (2019).","journal-title":"Oncoimmunology"},{"key":"72760_CR54","doi-asserted-by":"crossref","unstructured":"Russick, J. et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J. Immunother. Cancer8 (2020).","DOI":"10.1136\/jitc-2020-001054"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72760-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T06:05:35Z","timestamp":1726207535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-72760-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["72760"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-72760-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21380"}}